Descripción de la empresa
Calidi Biotherapeutics, Inc. operates as a clinical stage immuno-oncology company dedicated to developing allogeneic stem cell-based and enveloped virus platforms designed to potentiate and deliver oncolytic viruses within the United States market. The firm functions within the broader Healthcare sector, specifically inside the specialized Biotechnology industry, where it focuses on advancing therapies for oncology applications through its proprietary technology stack. As of the latest data, the company maintains a total market capitalization of $2.63M and employs a workforce of 29 individuals to execute its research and development initiatives. The combination of a sub-$3M market cap and zero reported annual revenue indicates that Calidi is an early-stage entity that has not yet achieved commercial product sales, positioning it as a capital-intensive venture relying on future regulatory approvals and clinical trial success to transition toward profitability.
Salud financiera
The company reports a net income of $-25,579,000 over the trailing twelve months, while its EBITDA stands at $-18,589,000, revealing a significant cost structure burden where operating expenses and other deductions heavily outweigh any minimal revenue generation. Although specific revenue figures for the trailing twelve months are not available in the current dataset, the substantial negative net income suggests that the firm is currently burning cash to fund its clinical trials and platform development. The free cash flow is recorded at $-11,853,875, indicating a consistent outflow of capital that limits immediate financial flexibility but is typical for biotechnology firms in the pre-commercialization phase. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, which reflects the lack of commercial sales volume necessary to generate a positive contribution margin or cover operating overheads. In terms of liquidity and leverage, the company holds $5.60M in cash against $2.56M in debt, resulting in a debt-to-equity ratio of 68.21 that suggests a moderately leveraged balance sheet relative to its equity base. The current ratio is 1.59, signaling that the company possesses sufficient current assets to cover its short-term liabilities, thereby maintaining adequate liquidity despite its negative earnings position. Furthermore, the return on equity is -700.6% and the return on assets is -109.8%, metrics that mathematically reflect the heavy losses being allocated against the company's equity and asset base, illustrating the high financial risk inherent in its current operational stage.
Evaluación de valoración
The trailing twelve-month P/E ratio is not applicable due to the lack of net income, whereas the forward P/E is listed as -0.27, a figure that underscores the expectation of continued negative earnings in the near term rather than a standard valuation based on current profitability. The price-to-book ratio is 0.47, indicating that the market values the company's equity at less than half of its book value, which often occurs when investors price in the risk of potential asset dilution or the difficulty of monetizing intangible research assets. Alternative valuation metrics such as the price-to-sales ratio are not available due to the absence of revenue data, while the EV/EBITDA stands at 0.02, a negligible multiple that highlights the extreme valuation compression typical of companies with negative earnings and minimal enterprise value. The stock price has exhibited significant volatility, trading within a 52-week range between a low of $0.21 and a high of $19.20, placing the current valuation context within a wide band of historical performance that reflects the speculative nature of the asset. With a beta of 1.42, the stock demonstrates price volatility that is 42% higher than the broader market, confirming its status as a high-risk equity suitable only for portfolios with a tolerance for extreme price swings.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as not available, precluding any direct comparison of earnings growth speed relative to revenue expansion due to the absence of sequential or comparative data points. Since the company does not pay dividends, the dividend yield is not applicable and the payout ratio is 0.0%, which confirms that the firm retains all available cash flow to reinvest into its clinical pipeline and research efforts rather than distributing returns to shareholders. This reinvestment strategy is characteristic of clinical-stage biotechs, where capital is directed toward advancing CLD-101 through its Phase 1b/2 clinical trial and further developing the enveloped virus platform to achieve regulatory milestones. Consequently, the overall growth and income profile is defined by a total lack of current cash generation or dividend income, relying entirely on external equity financing and the potential future monetization of its immuno-oncology assets to drive long-term value creation.